




Fig. 1





Fig. 2






Fig. 4




Fig. 5






Fig. 6




d6-DM = deuterated dextromethorphan; d3-DX = deuterated dextroamphetamine; PRX = paroxetine; Q = quinidine. Subjects received PRX 20 mg/d on days 1–20 and AVP-786 (d6-DM 30 mg/Q 4.75 mg BID) on days 13–20.

Fig. 7




d6-DM = deuterated dextromethorphan; d3-DX = deuterated dextropropofol; PRX = paroxetine; Q = quinidine. Subjects received AVP-786 (d6-DM 30 mg and Q 4.75 mg BID) on days 1-20 and PRX 20mg/d on days 9-20.

Fig. 8



d6-DM = deuterated dextromethorphan; d3-DX = deuterated dextrothorphan; DUL = duloxetine; Q = quinidine. Subjects received DUL 20 mg BID on days 1–13 and AVP-786 (d6-DM 30 mg/Q 4.75 mg BID) on days 6–13.

Fig. 9



d6-DM = deuterated dextromethorphan; d3-DX = deuterated dextropropofol; DUL = duloxetine; Q = quinidine. Subjects received AVP-786 (d6-DM 30 mg/Q 4.75 mg BID) on days 1–13 and DUL 20 mg BID on days 9–13.

Fig. 10